Samer El Hayek1†
Wael Foad1†
Renato de Filippis2†
Abhishek Ghosh3†Nadine Koukach1†Aala Mahgoub Mohammed Khier1
Sagun Ballav Pant4†Vanessa Padilla5†
Rodrigo Ramalho6†Hossameldin Tolba1†
Mohammadreza Shalbafan7*†- 1Medical Department, Erada Center for Treatment and Rehabilitation in Dubai, Dubai, United Arab Emirates
- 2Psychiatry Unit, Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy
- 3Postgraduate Institute of Medical Education and Research, Chandigarh, India
- 4Department of Psychiatry, Institute of Medicine, Tribhuvan University, Kathmandu, Nepal
- 5Department of Psychiatry and Behavioral Sciences, University of Miami, Miami, FL, United States
- 6Department of Social and Community Health, University of Auckland, Auckland, New Zealand
- 7Mental Health Research Center, Psychosocial Health Research Institute (PHRI), Department of Psychiatry, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
1 Introduction
The stigma surrounding persons living with substance use disorders (SUDs) is a ubiquitous phenomenon that has had detrimental effects on affected individuals, their families, healthcare providers, treatment outcomes, research, policies, and society as a whole (1). Studies suggest that the stigma toward SUDs exceeds that of other mental health conditions (2) and is a common obstacle to help-seeking behavior among individuals with SUDs (3, 4). One systematic review found that healthcare professionals typically hold negative attitudes toward people with SUDs, resulting in patients experiencing reduced empowerment and poorer treatment outcomes (5). As healthcare professionals are often the gatekeepers to treatment, they must be adequately trained and educated about managing SUDs. Medical bodies, educational institutes, and various governmental and non-governmental organizations are recognizing that substance use treatment, policies, and language need to evolve to provide better support for affected individuals (1).
In this opinion piece that brings the wisdom and experience of a multinational group of adult and addiction psychiatrists, we highlight the different sources of stigma faced by individuals with SUDs and how it impacts treatment-seeking and related outcomes. More importantly, we provide recommendations for holistic interventions to address stigma toward addiction and enhance the delivery of optimal care.
2 Stigma toward addiction and its impact on treatment
2.1 Where does stigma originate from?
Stigma toward SUDs comes from many sources including society, individuals living with SUDs themselves, their families, and healthcare professionals (6). Many factors can play a role in perpetuating this stigma, especially the longstanding societal view of addiction as a personal or moral failure (6, 7). In different societies and cultures, it is not uncommon for the community to label individuals with SUDs as worthless, weak, dangerous, criminals, incapable of holding jobs or forming families, and having deliberately chosen addiction. Some specific stereotypes faced by individuals with SUDs can be related to disadvantaged and vulnerable populations, such as those living in poverty or homelessness, minorities, and those who allow “peer pressure” to influence their drug use (8). In Nepal, individuals with a history of SUD continue to be perceived as lacking moral values, despite undergoing treatment, which can lead to relapse (9). One systematic thematic analysis of Indian newspaper articles explored online media’s attitudes and perceptions toward individuals with SUDs. Results showed that many articles propagated public stigma by using stigmatizing language, identifying people who use drugs with negative and unwanted qualities (10). Similarly, the media in New Zealand had often used terms such as “meth head” and “drug addict” when discussing individuals with SUDs (11). In Italy, schools, universities, and media outlets rarely convey the medical aspects of addictions, and SUDs are typically perceived as vices rather than diseases. Along the same lines, addiction treatment centers tend to be isolated and external to the general hospital setting (12, 13). Criminalizing drug use further fosters public stigma toward individuals with SUDs, through social and economic marginalization. Criminalization also diverts attention from the medical and public health models of addiction to a moral and punitive model. In India, for instance, this translates in the latest Narcotic Drugs and Psychotropic Substances policy limiting the access to evidence-based treatment, such as opioid agonist maintenance treatment and harm reduction strategies, by imposing restrictions on the duration and settings of treatment (14). Similarly, in Nepal, current laws remain harsh and add to the perception that individuals with SUDs are criminals who should be referred to the criminal justice system (15).
Individuals with SUDs and their family members experience significant internalized and affiliate stigma. Across cultures, internalized stigma is correlated with poorer quality of life (16) and delay in seeking treatment (17), especially in the initial stages of the illness (18). The Arab, Iranian, and Indian societies are collectivistic societies where family plays an essential role in fostering support and individuals’ decision-making. Hence, if one family member is affected by a SUD, others would attempt to provide support. However, families would also try hard to shield the affected member from the neighborhood and society to avoid stigma, which can lead to delays in treatment. In general, affiliate stigma tends to prevent families from providing the necessary medical support to their loved ones (19).
Healthcare professionals also hold negative perceptions and implicit biases toward individuals with SUDs. One study among primary care providers in New Zealand found that people who misuse prescription medications can be often stigmatized and offered limited harm reduction interventions (20). A systematic review of studies conducted in Western countries found that negative attitudes of healthcare professionals toward individuals with SUDs are common and contribute to suboptimal care (5). The general attitude of healthcare providers toward people with lived experience of mental illness is not positive in Iran, and attitudes toward those living with SUDs seem to be worse (21, 22). In many countries, including the Arab world and India, little enthusiasm is noted among psychiatry trainees to take up addiction psychiatry as a career option. Minimal exposure during residency, non-availability of evidence-based treatments and limited awareness about them, and significant public stigma might contribute to this. For similar reasons, practicing psychiatrists are sometimes uncomfortable with treating individuals with SUDs and are reluctant to initiate medications, perceiving this population as “challenging” and “difficult”.
2.2 How does stigma impact treatment?
Stigma is a negative driver for recovery from addiction. As previously mentioned, individuals who are stigmatized are less willing to engage in or seek medical treatment. Moreover, they may have to deal with associated fear, anger, isolation, trauma, or comorbid mental health disorders. This leads to care avoidance, self-directed early hospital discharge, and hesitance to call medical help or accept transport to a hospital after an overdose, all secondary to the fear of stigma and legal consequences (4). Stigma also impacts treatment availability, with a noted scarcity in the workforce that caters to the needs of individuals with SUDs, insufficiency in the number of treatment centers and available interventions, and limited support groups. Along the same lines, research into the treatment of addictions tends to be less prioritized than that of other mental illnesses. The stigmatizing language used to describe substance use behaviors, individuals with SUDs, and substance use treatment also creates other types of barriers for individuals who are on the road to recovery and re-integration into society, including at the level of their general healthcare, housing, employment, and insurance policies.
In many parts of the world, this translates into inappropriate and potentially hazardous treatment methodologies. For instance, in India, some privately owned rehabilitation centers deliver unethical and punitive treatments that lack evidence- and right-based medical approaches (23). In Iran, families can push their relatives with SUDs for involuntary admissions to “Campus”, which represents mandatory residence places that fail to provide proper treatment. In Nepal, people with SUDs have been traditionally treated out of health systems, in shoddy rehabilitation centers run by people with no experience and no standardized treatment protocol (15). In the Arab world, drug use can still be seen as a form of breakdown, possession by an evil spirit, or shortcoming of individual religious faith; and people may pursue a religious healer instead of a professional mental health practitioner to address this problem (24). But even when individuals seek professional help from psychiatrists or other allied medical health professionals, they can certainly be subject to inaccurate treatment approaches, highlighting the need for improving the awareness of the different stakeholders about the available evidence-based interventions.
3 Discussion
There is an urgent need to combat the stigma surrounding SUDs. Research on stigma interventions for providers who treat individuals with SUDs increased in recent years, indicating greater worldwide attention to the negative impact of stigma (25). Table 1 presents a comprehensive summary of potential interventions and strategies to decrease stigma toward addiction and individuals living with SUDs. By recognizing the enormous challenge that stigma poses to communities, and by revising the words and terms used when discussing matters of addiction and the people living with it, major reforms can occur. Decriminalizing drug use is another pivotal step that can guide the way. This measure not only decreases stigma but also allows for a shift in resources toward prevention and treatment, promoting an approach that prioritizes healing over punishment.
Table 1 Strategies to reduce stigma related to addiction and individuals with SUDs.
On this path of improvement, it is necessary to highlight some of the extensive efforts, campaigns, and work-in-progress initiated to battle the stigma against SUDs. For instance, in the United States, the Substance Abuse and Mental Health Services Administration (SAMHSA) and the National Institute on Drug Abuse (NIDA) continue to make widespread efforts to educate and break the stigma. In Egypt, the Ministry of Health has re-launched its “You Can, Without It” campaign for the fifth year in a row to aid individuals in recovery in avoiding relapse. Erada Center for Treatment and Rehabilitation in Dubai has launched for the past four years the “Masmooh” Campaign, a television/radio initiative that aims to educate the community about the nature of SUDs and promote greater understanding of the role of forgiveness in helping individuals recover. “Masmooh”, which means “permitted”, seeks to promote forgiveness in society to help re-integrate individuals with SUDs into their communities and give them a sense of hope. New Zealand has a strong history of health promotion, prevention, and anti-discrimination advocacy, with various campaigns targeting non-behavioral addictions, such as “Say Yeah, Nah”, “Go the distance”, and ‘Changing Minds’. Worldwide, several countries, governments, institutions, and educational bodies have shared online material to promote SUD-related anti-stigma campaigns and provide training and workshops for policymakers, healthcare professionals, educators, employers, faith leaders, youth, and the public. Equally important, major medical journals have been more keen on publishing about the topic of stigma toward SUDs in a compounded effort to educate the public (26).
Still, more work is needed. We, as psychiatrists, advocate for a stigma-free approach when treating individuals with SUDs. Such an approach includes actively listening to the person’s story, using destigmatizing language (27, 28), avoiding medical jargon, and ensuring to ask every individual how comfortable they feel talking about their substance use and how ready they are to change their use. Treatment should be provided in an individualized manner. Importantly, the approach should be free from judgment and prejudice, building trust by respecting the person’s rights for confidentiality and choice of treatment strategies, and respecting their dignity, beliefs, and culture. Autonomy and freedom to choose or not choose treatment or any particular treatment is essential. While using a motivational interviewing approach, providers should actively work on offering evidence-based treatments, including pharmacological interventions and prompt referral to medication-assisted treatments, individual and group therapies, and referral to peer support groups, such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) meetings. Emphasis is on the adoption of a harm-reduction approach, including the provision of a naloxone rescue kit and encouragement of safe injecting practices. This helps to highlight that the problem is substance use-related harm, not the person nor the substance use. Of equal significance is the incorporation of a trauma-informed care approach for all individuals with SUDs (29). Alternatively, using analogies of chronic non-communicable diseases (e.g., hypertension, diabetes mellitus) can be helpful for individuals to understand their condition. Lastly, instilling hope is of utmost importance, through educating people and their families that SUD is a treatable medical condition, not a choice, and that the person is never defined by their drug use. In the end, fostering a more accepting society involves numerous avenues, yet it always starts with grassroots initiatives, such as our language choices in everyday clinical discourse.
Author contributions
SEH: Conceptualization, Data curation, Investigation, Writing – original draft. WF: Conceptualization, Data curation, Writing – original draft. RdF: Conceptualization, Data curation, Writing – review & editing. AG: Data curation, Writing – review & editing. NK: Data curation, Writing – review & editing. AMMK: Data curation, Writing – review & editing. SP: Data curation, Writing – review & editing. VP: Data curation, Writing – review & editing. RR: Data curation, Writing – review & editing. HT: Data curation, Writing – review & editing. MS: Conceptualization, Data curation, Supervision, Writing – review & editing.
Funding
The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Zwick J, Appleseth H, Arndt S. Stigma: how it affects the substance use disorder patient. Subst Abuse Treatment Prevention Policy (2020) 15:50. doi: 10.1186/s13011-020-00288-0
2. Barry CL, Mcginty EE, Pescosolido BA, Goldman HH. Stigma, discrimination, treatment effectiveness, and policy: public views about drug addiction and mental illness. Psychiatr Serv (2014) 65:1269–72. doi: 10.1176/appi.ps.201400140
3. Kelly JF, Westerhoff CM. Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms. Int J Drug Policy (2010) 21:202–7. doi: 10.1016/j.drugpo.2009.10.010
4. Aronowitz S, Meisel ZF. Addressing stigma to provide quality care to people who use drugs. JAMA Network Open (2022) 5:e2146980–e2146980. doi: 10.1001/jamanetworkopen.2021.46980
5. van Boekel LC, Brouwers EP, Van Weeghel J, Garretsen HF. Stigma among health professionals towards patients with substance use disorders and its consequences for healthcare delivery: systematic review. Drug Alcohol Depend (2013) 131:23–35. doi: 10.1016/j.drugalcdep.2013.02.018
6. Yang LH, Wong LY, Grivel MM, Hasin DS. Stigma and substance use disorders: an international phenomenon. Curr Opin Psychiatry (2017) 30:378–88. doi: 10.1097/YCO.0000000000000351
7. Kulesza M, Larimer ME, Rao D. Substance Use Related Stigma: What we Know and the Way Forward. J Addict Behav Ther Rehabil (2013) 2(2):782. doi: 10.4172/2324-9005.1000106
8. NIDA. Stigma and discrimination (2022). National Institute on Drug Abuse. Available at: https://nida.nih.gov/research-topics/stigma-discrimination (Accessed 17 September 2023).
9. Bhandari TR, Khatiwada B, Rajbhandari B, Bestman A, Mistry SK, Rayamajhee B, et al. A qualitative study to understand drivers of psychoactive substance use among Nepalese youth. PloS One (2021) 16:e0259021. doi: 10.1371/journal.pone.0259021
10. Ghosh A, Naskar C, Sharma N, Fazl ER, Choudhury S, Basu A, et al. Does online newsmedia portrayal of substance use and persons with substance misuse endorse stigma? A qualitative study from India. Int J Ment Health Addict (2022) 20:3460–78. doi: 10.1007/s11469-022-00859-1
11. New Zealand drug foundation. New Zealand Drug Foundation submission on the mental health and addiction inquiry. Aotearoa, New Zealand: New Zealand Drug Foundation (2019).
12. EMCDDA. Italy, country drug report 2019. Lisbon, Portugal: European Monitoring Center for Drugs and Drug Addiction (2019).
13. Bramness JG, Leonhardt M, Dom G, Batalla A, Flórez Menéndez G, Mann K, et al. Education and training in addiction medicine and psychology across Europe: A EUFAS survey. Eur Addict Res (2023), 1–11. doi: 10.1159/000531502
14. Ambekar A, Rao R, Agrawal A. India’s National Narcotic Drugs and Psychotropic Substances policy 2012: a 20th century document in the 21st century. Int J Drug Policy (2013) 24:374–5. doi: 10.1016/j.drugpo.2013.01.001
15. Pant SB, Gurung B, Howard J. Recovery and rehabilitation from alcohol, substance use and related disorders in Nepal: call for paradigm shift. J Psychosocial Rehabil Ment Health (2023) 10:131–4. doi: 10.1007/s40737-023-00337-4
16. Sarkar S, Balhara YPS, Kumar S, Saini V, Kamran A, Patil V, et al. Internalized stigma among patients with substance use disorders at a tertiary care center in India. J Ethn Subst Abuse (2019) 18:345–58. doi: 10.1080/15332640.2017.1357158
17. Hammarlund R, Crapanzano KA, Luce L, Mulligan L, Ward KM. Review of the effects of self-stigma and perceived social stigma on the treatment-seeking decisions of individuals with drug- and alcohol-use disorders. Subst Abuse Rehabil (2018) 9:115–36. doi: 10.2147/SAR.S183256
18. Pelullo CP, Curcio F, Auriemma F, Cefalo G, Fabozzi A, Rossiello R, et al. The discrimination against, health status and wellness of people who use drugs in Italian services: A survey. Medicina (Kaunas) (2019) 55(10):662. doi: 10.3390/medicina55100662
19. New Zealand drug foundation. Scoping of a destigmatisation programme on drug use and drug dependence. A report for the Ministry of Health by the New Zealand Drug Foundation. Aotearoa, New Zealand: New Zealand Drug Foundation (2015).
20. Butler R, Sheridan J. Innocent parties or devious drug users: the views of primary healthcare practitioners with respect to those who misuse prescription drugs. Harm Reduct J (2010) 7:21. doi: 10.1186/1477-7517-7-21
21. Shalbafan M, Rashedi V, Seddigh R, Najarzadegan M, Azarpajouh T, Ahmadkhaniha H, et al. Validity and reliability of the Persian version of “drug-related knowledge and attitude questionnaire” among Iranian medical students. J Addictive Dis (2020) 38:489–94. doi: 10.1080/10550887.2020.1787769
22. Movahedi S, Shariat SV, Shalbafan M. Attitude of Iranian medical specialty trainees toward providing health care services to patients with mental disorders. Front Psychiatry (2022) 13:961538. doi: 10.3389/fpsyt.2022.961538
23. Joseph S, Hemalatha K. Addiction treatment in India: Legal, ethical and professional concerns reported in the media. Indian J Med Ethics (2021) Vi:306–13. doi: 10.20529/IJME.2021.030
24. Alsuwaidi H. Understanding the barriers to integration to society, recovering patient from addiction face: qualitative study in UAE. [Master’s thesis]. Boston, Massachusetts: Harvard Medical School (2019). Available at: http://nrs.harvard.edu/urn-3:HUL.InstRepos:42057409.
25. Bielenberg J, Swisher G, Lembke A, Haug NA. A systematic review of stigma interventions for providers who treat patients with substance use disorders. J Subst Abuse Treat (2021) 131:108486. doi: 10.1016/j.jsat.2021.108486
26. Mcginty EE, Barry CL. Stigma reduction to combat the addiction crisis - developing an evidence base. N Engl J Med (2020) 382:1291–2. doi: 10.1056/NEJMp2000227
27. INPUD. Words matter! INPUD & ANPUD language statement & reference guide. London: International Network of People Who Use Drugs (2020).
28. Volkow ND, Gordon JA, Koob GF. Choosing appropriate language to reduce the stigma around mental illness and substance use disorders. Neuropsychopharmacology (2021) 46:2230–2. doi: 10.1038/s41386-021-01069-4
Keywords: stigma, social stigma, discrimination, addiction, substance use disorder, psychiatry
Citation: El Hayek S, Foad W, de Filippis R, Ghosh A, Koukach N, Mahgoub Mohammed Khier A, Pant SB, Padilla V, Ramalho R, Tolba H and Shalbafan M (2024) Stigma toward substance use disorders: a multinational perspective and call for action. Front. Psychiatry 15:1295818. doi: 10.3389/fpsyt.2024.1295818
Received: 17 September 2023; Accepted: 18 January 2024;
Published: 01 February 2024.
Edited by:
Wulf Rössler, Charité University Medicine Berlin, GermanyReviewed by:
Atefeh Mohammadjafari, Department of psychiatry Tehran University of Medical Science, IranRahim Badrfam, Alborz University of Medical Sciences, Iran
Copyright © 2024 El Hayek, Foad, de Filippis, Ghosh, Koukach, Mahgoub Mohammed Khier, Pant, Padilla, Ramalho, Tolba and Shalbafan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mohammadreza Shalbafan, c2hhbGJhZmFuLm1yQGl1bXMuYWMuaXI=
†ORCID: Samer El Hayek, orcid.org/0000-0002-7975-6104
Wael Foad, orcid.org/0000-0002-2255-726X
Renato de Filippis, orcid.org/0000-0001-6928-1224
Abhishek Ghosh, orcid.org/0000-0002-0988-7694
Nadine Koukach, orcid.org/0000-0002-4366-3352
Sagun Ballav Pant, orcid.org/0000-0002-7335-6759
Vanessa Padilla, orcid.org/0000-0001-8557-5548
Rodrigo Ramalho, orcid.org/0000-0002-2372-6854
Hossameldin Tolba, orcid.org/0009-0005-5859-5857
Mohammadreza Shalbafan, orcid.org/0000-0002-4536-3441